{
    "clinical_study": {
        "@rank": "52123", 
        "arm_group": [
            {
                "arm_group_label": "Androxal 25 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Androxal 250 mg", 
                "arm_group_type": "Experimental", 
                "description": "supratherapeutic dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Moxifloxacin 400 mg", 
                "arm_group_type": "Other", 
                "description": "positive control"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase I, single-site, randomized, double-blinded, double-dummy, placebo- and\n      positive-controlled, 4-period crossover study to evaluate the effect of two dose levels of\n      Androxal on cardiac repolarization. Baseline ECGs will be obtained prior to dosing in each\n      Period and ECGs will be obtained during expected peak plasma concentrations of Androxal and\n      the positive control.\n\n      In each Treatment Period subjects will be admitted to a Clinical Research Unit where study\n      drug will be administered as three (3) daily single doses. Treatment Periods will be\n      separated by a washout of at least 7 days between Periods."
        }, 
        "brief_title": "A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Generally healthy males as determined by history and physical examination\n\n          2. Between the ages of 18 and 60, inclusive\n\n          3. Clinical laboratory test results within the normal reference ranges for the\n             investigative site or results with acceptable deviations that are judged by the\n             principal investigator to be not clinically significant\n\n          4. Vital signs (after 5 minutes resting in a supine position)\n\n               -  Systolic blood pressure (SBP) 90-140 mmHg, and\n\n               -  Diastolic blood pressure (DBP) 50-90 mmHg, and\n\n               -  Pulse 45-100 bpm Note: subjects with vital signs outside the above ranges may be\n                  eligible for the study if the Investigator feels that the results are not\n                  clinically significant and will not impact study conduct.\n\n          5. Body mass index (BMI) \u226525 to \u226442 kg/m2 at Screening\n\n          6. Are reliable and willing to be available for the duration of the study, abiding by\n             the policies and procedures of the clinical trials unit\n\n          7. Have given written informed consent\n\n          8. Subject must be able to speak, read and understand English or Spanish and be willing\n             and able to provide written informed consent in English or Spanish on an\n             Institutional Review Board (IRB)-approved form prior to the initiation of any study\n             procedures. Subject must have signed and dated a written informed consent form (ICF)\n             before undergoing any study related activities, including discontinuation of any\n             prohibited medications.\n\n        Exclusion Criteria:\n\n          1. Repros employee or investigative site personnel and their immediate families\n\n          2. Participation in a clinical trial within the past 30 days or receipt of any\n             investigational agent or study treatment within 30 days or 5 half-lives, whichever is\n             longer, prior to Screening\n\n          3. Known hypersensitivity to Clomid\n\n          4. Known allergy to moxifloxacin\n\n          5. Abnormal electrocardiogram that, after the option of repeating any such findings, in\n             the opinion of the Investigator and/or Sponsor may interfere with any aspect of study\n             conduct or interpretation of results including:\n\n               -  an abnormality of cardiac rhythm other than sinus arrhythmia\n\n               -  QTcF > 450 msec\n\n               -  QTcF < 300 msec\n\n               -  PR interval >200 msec\n\n               -  QRS > 110 msec\n\n               -  abnormal T wave morphology that will impair the ability to measure the QT\n                  interval reliably\n\n          6. History of congenital long QT syndrome or known history of QTc interval prolongation\n             or family history of congenital long QT syndrome\n\n          7. Evidence of significant cardiac disease, for example, arrhythmia or unexplained\n             syncope within the last year\n\n          8. History of myocardial infarction, unstable angina, symptomatic heart failure,\n             ventricular dysrhythmia,\n\n          9. History of thrombophlebitis, thromboembolic disorder or cerebrovascular accident\n\n         10. Evidence of significant respiratory or hepatic disease\n\n         11. Use of cigarettes or any tobacco product within 2 weeks prior to Screening and while\n             participating in the study\n\n         12. Use of any medications other than acetaminophen or aspirin (prescription or\n             over-the-counter), herbal tea , energy drinks, supplements, within 5 days of dosing\n             (prior to first dose of study medications), with the exception of those approved by\n             the Investigator and Sponsor\n\n         13. Use of drugs of abuse and/or positive findings on drug screen\n\n         14. Known active infection with HIV or hepatitis B or C."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117830", 
            "org_study_id": "ZA-108"
        }, 
        "intervention": [
            {
                "arm_group_label": "Androxal 25 mg", 
                "intervention_name": "Androxal 25 mg capsules", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Androxal 250 mg", 
                "intervention_name": "Androxal 250 Capsules", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo Capsules", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Moxifloxacin 400 mg", 
                "intervention_name": "Moxifloxacin 400 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clomiphene", 
                "Norgestimate, ethinyl estradiol drug combination", 
                "Moxifloxacin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "To determine", 
            "effects", 
            "once", 
            "daily", 
            "oral doses", 
            "Androxal"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The placebo-subtracted change of the QTc interval from Baseline (\u0394\u0394QTc) defined as: the change of QTc from the subject-specific and period-specific Baseline (\u0394QTc), less the time-matched placebo value of change of QTc", 
            "measure": "The placebo-subtracted change of the QTc interval from Baseline (\u0394\u0394QTc) defined as: the change of QTc from the subject-specific and period-specific Baseline (\u0394QTc), less the time-matched placebo value of change of QTc", 
            "safety_issue": "Yes", 
            "time_frame": "64 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117830"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Repros Therapeutics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Repros Therapeutics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}